Traduction de «al cancer risk » (Néerlandais → Français) :

TERMINOLOGIE

controle van zwangerschap met verhoogd risico [high-risk]
Surveillance d'une grossesse à haut risque

TRADUCTIONS EN CONTEXTE

The study confirmed a significant benefit for Femara versus tamoxifen in reducing the risk of distant metastases and the overall risk of breast cancer recurrence.
Cette étude a confirmé les avantages importants de Femara comparé au tamoxifène pour réduire le risque de métastases distantes et globalement celui de récidive du cancer du sein.

Table 8: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)
Table 10: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)

Also supporting the broad expansion have been landmark data first presented in 2008, and published in early 2009 in “The New England Journal of Medicine,” that showed the significant anti-cancer benefit of Zometa in reducing the risk of cancer recurrence or death in premenopausal women with hormone-sensitive, earlystage breast cancer.
Cette large progression a été soutenue par de nouveaux résultats d’une étude pivot présentés initialement en 2008 et publiés début 2009 dans «The New England Journal of Medicine» faisant état des bénéfices anticancer importants du Zometa dans le risque de récidive ou de décès chez les femmes préménopausées atteintes d’un cancer du sein hormono-dépendant précoce.

30.Lippman SM , Klein EA, Goodman PJ et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
30. Lippman SM , Klein EA, Goodman PJ et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Results from a Phase III study involving Afinitor in pancreatic neuroendocrine tumors (NET), a rare and aggressive form of cancer with limited treatment options, showed that Afinitor extended median progression-free survival from 4.6 to 11 months versus placebo and reduced the risk of cancer progression by 65%.
(TNE) du pancréas, une forme rare et agressive de cancer difficile à traiter, ont montré qu’Afinitor allongeait la survie moyenne sans progression de la maladie de 4,6 à 11 mois par rapport à un placebo et réduisait de 65% le risque de progression du cancer.

The use of Magnetic Resonance Imaging of the Breast for screening of women at high risk for breast cancer.
Magnetic Resonance Imaging for the detection of breast abnormalities.

28. Law J, Faulkner K. Concerning the relationship between benefit and radiation risk, and cancers detected and induced, in a breast screening programme.
29. Law J, Faulkner K. Concerning the relationship between benefit and radiation risk, and cancers detected and induced, in a breast screening programme.

27. Law J, Faulkner K, Young KC. Risk factors for induction of breast cancer by X-rays and their implications for breast screening.
28. Law J, Faulkner K, Young KC. Risk factors for induction of breast cancer by X-rays and their implications for breast screening.

12. Ringash J. Preventive health care, 2001 update: screening mammography among women aged 40-49 years at average risk of breast cancer.
13. Ringash J. Preventive health care, 2001 update: screening mammography among women aged 40-49 years at average risk of breast cancer.

A study in premenopausal women with hormone-sensitive, early-stage breast cancer showed the addition of Zometa to hormone therapy after surgery significantly reduced the risk of recurrence or death beyond benefits achieved with hormone therapy alone.
Une étude, portant sur des femmes préménopausées atteintes d’un cancer du sein au stade précoce, a montré que l’adjonction de Zometa à un traitement hormonal après intervention chirurgicale permettait une réduction significative du risque de récidive ou de décès, au-delà des bénéfices obtenus par la seule thérapie hormonale.